Review

BET Proteins as Attractive Targets for Cancer Therapeutics

Joanna Sarnik 1, Tomasz Popławski 2 and Paulina Tokarz 2,*

Abstract: Transcriptional dysregulation is a hallmark of cancer and can be an essential driver of cancer initiation and progression. Loss of transcriptional control can cause cancer cells to become dependent on certain regulators of gene expression. Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate the expression of multiple genes involved in carcinogenesis. BET inhibitors (BETis) disrupt BET protein binding to acetylated lysine residues of chromatin and suppress the transcription of various genes, including oncogenic transcription factors. Phase I and II clinical trials demonstrated BETis’ potential as anticancer drugs against solid tumours and haematological malignancies; however, their clinical success was limited as monotherapies. Emerging treatment-associated toxicities, drug resistance and a lack of predictive biomarkers limited BETis’ clinical progress. The preclinical evaluation demonstrated that BETis synergised with different classes of compounds, including DNA repair inhibitors, thus supporting further clinical development of BETis. The combination of BET and PARP inhibitors triggered synthetic lethality in cells with proficient homologous recombination. Mechanistic studies revealed that BETis targeted multiple essential homologous recombination pathway proteins, including RAD51, BRCA1 and CtIP. The exact mechanism of BETis’ anticancer action remains poorly understood; nevertheless, these agents provide a novel approach to epigenome and transcriptome anticancer therapy.

Keywords: BET; BETi; cancer; DNA repair; homologous recombination; transcription

1. Introduction

Cell identity and its proper functioning are determined by the transcriptome. The single-cell transcriptome is regulated by tens of thousands of promoter and enhancer regions and a few hundred super-enhancer—clusters of enhancers binding master transcription factors and mediators [1–3]. The control of the transcriptome is even more complex given epigenetic changes, including noncoding RNA synthesis, DNA methylation and histone modification. Histone acetylation at lysine residues is a reversible and highly dynamic modification frequently disturbed in cancer cells, making it an attractive anticancer therapy target. Histone acetylation at lysine residues is a reversible and highly dynamic modification frequently disturbed in cancer cells, making it an attractive anticancer therapy target. Histone acetylation under the control of histone acetyltransferases (HATs), which are the “writers”, bromodomain (BRD) proteins, which are the “readers”, and histone deacetylases (HDACs) and sirtuins, which together are the “erasers”.

Transcription dysregulation is a hallmark of cancer. Loss of transcriptional control leads to changes in gene expression, which could be a driving force behind carcinogenesis. Defective DNA damage response (DDR) and repair pathways are cancer cells’ common features that trigger disease initiation and progression. The efficacy of DNA damage repair is provided by the proper structure of repair proteins and a sufficient amount of DDR and repair pathway members. Alterations in DDR and repair genes’ transcription may have significant consequences for carcinogenesis, response to treatment and acquisition of resistance. In this review, we discuss the role of epigenetic readers in the transcriptional control of DNA repair genes and the implications for carcinogenesis and anticancer therapy.
2. BET Proteins' Function

The bromodomain and extraterminal domain (BET) family belongs to BRD proteins and comprises four evolutionarily conserved members, including ubiquitously expressed BRD2, BRD3 and BRD4 and a testis-specific BRDT [3,4]. The BET family is characterised by the presence of two N-terminal bromodomains, BD1 and BD2, and an extraterminal domain (ET) (Figure 1) [4–6]. BRD4 and BRDT also contain a C-terminal motif (CTM) that facilitates the recruitment of transcriptional regulators, including the positive transcription elongation factor (P-TEFb). Among these domains, BD1 and BD2 have a conserved sequence of 110 amino acids that creates a hydrophobic binding pocket for acetylated lysine residues on histones and other proteins [7,8]. BD domains are composed of a four-helix bundle (αZ, αA, αB and αC) and two loops, ZA and BC. The ET domain is a conserved region of ~80 amino acids that recruits transcription effector proteins [9–12]. The CTD domain is a conserved region of ~40 amino acids responsible for the recruitment of P-TEFb [13,14].

Figure 1. Arrangement of domains in the human bromodomain and extraterminal domain (BET) family of proteins; BRD2, BRD3, BRD4 and BRDT. BET proteins contain two N-terminal bromodomains (BD1 and BD2), an extraterminal domain (ET) and a C-terminal motif (CTM).

BRD2 (alias RING3 or FSRG1) is a serine/threonine kinase that is a component of a mediator—a multiprotein complex functioning as a transcriptional co-activator of RNA polymerase II (Pol II) [15]. BRD2 recruits the E2F-1 and E2F-2 transcription factors and assists in the Pol II-mediated transcription in hyperacetylated chromatin, thereby coupling histone acetylation to transcription [16–18]. Along with E2F proteins, BRD2 activates the promoters of several cell cycle regulatory genes, including cyclin A, cyclin D11 and cyclin E [18,19]. Moreover, BRD2 was shown to exert histone chaperone activity [17].

BRD3 (alias ORFX) is a serine/threonine kinase that facilitates Pol II transcription through hyperacetylated nucleosomes independent of P-TEFb [17]. BRD3 might cooperate with BRD4 to recruit P-TEFb to the chromatin and thus promote transcriptional activation [20]. BRD3 binds the GATA1 transcription factor in an acetylation-dependent manner and facilitates stable association with chromatin [21,22]. BRD3 together with BRD4 are characterised to be required for IL-1β- or TNF-α-induced transcription [20].

BRDT (bromodomain, testis-specific, alias BRD6) is specifically expressed in testis and ovaries [23]. BRDT modulates gene expression as part of the splicing and participates in chromatin remodelling [7,24]. BRDT interacts with acetylated histone H4 and might assist in the removal of acetylated histones during spermatogenesis [8].

BRD4 (alias MCAP or Hunk1) is a serine kinase and is the most extensively studied member of the BET family. It is a chromatin-binding factor with a preference for acetylated Lys-14 on histone H3 and Lys-5/12 on H4 [6]. BRD4 comprises three splice isoforms, A, B and C, and only isoform A contains the CTD domain [25]. BRD4 isoform A has a well-established role in transcriptional modulation, mainly as a transcriptional co-activator of P-TEFb, which stimulates Pol II transcription (Figure 2) [13,14]. BRD4 binding facilitates P-TEFb recruitment to chromatin. Moreover, a core component of P-TEFb was identified as cyclin-dependent kinase-9 (CDK9)—a target in chronic lymphocytic leukaemia and
necessary for MYC-mediated transcription regulation [26–28]. BRD4 marks transcriptional start sites of growth-associated genes at the M/G1 transition throughout mitosis [29].

![Figure 2. Function of the bromodomain and extraterminal domain 4 (BRD4) protein and the role of its inhibition in anticancer therapy. (A) BRD4 binds to acetylated histones and, via its C-terminal motif (CTD), facilitates the recruitment of the positive transcription elongation factor (P-TEFb) to chromatin. BRD4 enables the interaction among transcription factors (TF), the mediator complex and P-TEFb, which result in the phosphorylation of RNA polymerase II (RNA pol II) on serine 2 of its C-terminal domain, thereby stimulating transcriptional elongation. (B) BET inhibitors (BETis) dissociate BRD4 from acetylated histones, thus repressing the transcription of oncogenes.](image-url)

### 3. BET Proteins in Cancer

BET and, in particular, BRD4 have been implicated in human diseases, especially cancer. Clinical research provides direct evidence of the oncogenic roles of BRD3 and BRD4 [30–32]. BRD3 and BRD4 genes translocation t(15;19) leads to a fusion protein with nuclear protein in testis (NUT), which causes a rare, but aggressive form of human squamous carcinoma. The BRD-NUT oncoprotein contributes to the carcinogenesis of NUT midline carcinoma (NMC). Genome-wide sequencing revealed that BRD3/4-NUT rearrangements are major oncogenic drivers of NMC [33]. The BRD4-NUT oncoprotein blocks differentiation in NMC cells by maintaining MYC expression, and BRD4-NUT suppression results in NMC cell differentiation [32,34]. In addition to BRD-NUT-driven malignancies, the BRD4 gene was found to be amplified across 20 types of common cancers [35]. Furthermore, BRD4 levels are upregulated in various tumours, leading to aberrant expression of growth-promoting genes and transcription factors [36–38]. A primary downstream target of BRD4 is MYC—a member of the myc family of transcription factors encoded by the proto-oncogene, which is frequently deregulated in cancer [37,39]. The first indication that MYC regulation might depend on BET came from the observation that P-TEFb is not recruited to the MYC locus in BRD4 knockdown cells, suggesting that BRD4 is critical for MYC transcription [13]. Besides MYC, BET influences the expression
of other transcription factors such as ERG, c-Myb, E2F1 and nuclear factor κB (NF-κB) (reviewed in [40]).

4. BET Inhibitors Target MYC

MYC has long been considered a compelling therapeutic target because of its role in a range of human malignancies. Despite the urgent need to suppress this oncogenic driver, MYC had been deemed “undruggable” due to a large protein–protein interaction interface and its lack of a deep protein pocket [41]. The advent of BET inhibitors (BETis) was motivated by previous research establishing BRD4 as a promising anticancer target [13]. The first two inhibitors that competitively bind the acetyl-lysine recognition motif (bromodomain) of BET proteins were presented in 2010. I-BET (GSK525762), a benzodiazepine derivative, targets the expression of inflammatory genes [42]. JQ1, a novel thieno-triazolo-1,4-diazepine, selectively inhibits all BET family members: BRD2, BRD3, BRD4 and BRDT [39]. JQ1 displaces BRD4 from nuclear chromatin in cells and induces differentiation in NMC cells. A study in NMC xenograft tumours confirmed the antiproliferative and pro-apoptotic effects of JQ1. The publications on the first BETis and the accessibility of JQ1 accelerated the preclinical studies. Soon, it was demonstrated that BETis provide effective treatment against multiple myeloma (MM), acute myeloid leukaemia (AML), Burkitt’s lymphoma and mixed-lineage leukaemia (MLL)-rearranged leukaemias [36–38,43]. All the above papers emphasised the mode of the action of BETis, at least in part, due to the suppression of MYC transcription and cell cycle arrest. Most attention has been paid to selective targeting of critical oncogenic drivers such as MYC in multiple tumour types by BETi. The mechanism of MYC suppression by BETi is mainly conducted by the loss of BET at the MYC super-enhancer, a regulatory DNA fragment comprising multiple enhancers binding diverse transcription factors to provide the gene expression necessary for cell identity [1,3]. In many instances, BETis suppressed MYC transcription in a dose-dependent manner [36,37]. This downregulation is particularly pronounced in MYC-amplified tumours [44]. Although in most cases, there is a positive correlation between MYC-amplification and sensitivity to BETis, surprisingly, tumours lacking MYC amplification respond to the BETi treatment similarly to those with MYC amplification, suggesting that there are other targets within a cell for BETis [44–46]. Clinical trials confirmed that MYC expression fails to predict sensitivity to BETis in haematological malignancies and thus questioned its validity as a predictive biomarker [47]. The complexity between MYC expression and response to BETis may be due to the multiple mechanisms of the BET proteins’ function.

5. BET Inhibitors in Clinical Trials

Although JQ1 was a promising drug candidate in preclinical studies, with excellent oral bioavailability and good pharmacokinetics, its short half-life (one hour in vivo) limits its clinical application [39]. Nevertheless, JQ1 was the first compound, together with I-BET, that allowed for the mechanistic study of BET proteins’ functions and their oncogenic potential. Over the last few years since the development of JQ1 in 2010, a few new BETis have been synthesised and evaluated in clinical studies (Table 1; reviewed in [48,49]).

As described above, the oncogenic role of BRD was initially described in NMC, which is driven by NUT translocation, usually involving BRD3 or BRD4. The BRD-NUT fusion oncoprotein results in aberrant BRD activity. The promising data from preclinical studies on the efficacy of BETis against NMC led to a first published clinical trial of BETi, OTX015 (MK-8628) [50]. This first proof-of-concept small-scale study evaluated the antitumor activity of OTX015, a JQ1 analogue, in four advanced-stage NMC patients with confirmed BRD4-NUT fusions. Three out of four patients responded to the treatment, including two patients with rapid tumour regression and a third with disease stabilisation (SD). Two patients achieved an overall survival (of 18 mo and 19 mo) longer than the median survival of 6.7 mo [50,51]. Complementary studies on NMC showed that eight out of ten patients responded to OTX015 at 80 mg once daily, including three patients with partial response.
(PR) and three patients with SD for 1.8–8.4 mo [52]. Confirmed PR (two out of nineteen patients) and SD (seven out of nineteen patients) has been observed for NMC patients treated with GSK525762 [53]. Although clinical responses in NMC patients to BETis have been observed, these trials showed less-than-anticipated efficacy coming from preclinical observations.

Most BETis achieve the cytostatic effect as a single agent at an approximate concentration of 500 nM across different cancer cell lines (reviewed in [54]). Such an effective concentration in preclinical studies translates into high concentrations in clinical settings, approximately 80 mg daily. Most clinical trials reported severe dose-limiting toxicities (DLTs), including thrombocytopenia, neutropenia, anaemia, gastrointestinal disorders, hyperbilirubinaemia, fatigue, headache and pain [47,52,55]. Hopefully, the adverse events were manageable and reversible. The first two clinical trials on OTX015 were published in the same issue of *The Lancet Haematology* journal in 2016. Both studies were aimed to establish the recommended dose of OTX015 in patients with acute leukaemia [55], lymphoma and MM [47]. Both studies led to the same recommendation of a drug dose of 80 mg once daily for single-agent oral OTX015 use in patients on a 14 d on and 7 d off schedule. Thrombocytopenia was the most reported DLT (96% patients). Due to the reversibility of thrombocytopenia after treatment interruption, the DLT was attributed to grade 4 [47]. No DLTs were recorded until 160 mg/d in five patients with acute leukaemia [55]. Complementary phase II studies recommended a dose of OTX015 in patients with castrate-resistant prostate cancer (CRPR), NMC and nonsmall-cell lung cancer at 80 mg once daily with continuous dosing [52]. DLTs included ALT, hyperbilirubinemia and thrombocytopenia grade 3 and 4.

AZD5153 is a bivalent BETi that was optimised to interact with both bromodomains of BRD4 [56]. Preclinical studies showed that AZD5153 is effective as an anticancer agent at significantly lower concentrations than most BETis [57,58]. AZD5153 inhibited the growth of haematological, prostate and thyroid cancer cell lines at a concentration <150 nM [57–59]. Most haematological cell lines responded to the treatment at a concentration <25 nM [57]. Importantly, AZD5153 demonstrated a cytotoxic effect at a concentration 100 nM and tumour regression at concentrations 2.5–10 mg/kg for AML and prostate cancer xenografted tumours [57–59]. AZD5153 progressed to clinical trial, which reported similar DLTs as for OTX015, indicating that although BETis’ chemical structure is diverse, toxicities may be shared across BETis [60]. A dose escalation study of a new BETi, BAY1238097, in eight patients with solid cancers was prematurely terminated due to DLTs [61]. ABBV-075 is a BETi that strongly inhibits BRD2, BRD4 and BRDT, but not BRD3 (K_i = 1–2.2 nM). A large screen of 147 haematological and solid cancer cell lines demonstrated that ABBV-075 inhibited cell proliferation at concentrations similar to AZD5153 and was more effective against haematological than solid tumours malignancies [62]. A dose escalation study recommended ABBV-075 monotherapy at a concentration of 1.5 mg for the daily schedule, 2.5 mg for 4/7 and 3 mg for 3/7 for patients with advanced solid tumours [53]. Among 71 patients with solid tumours, 26 (43%) had SD. Despite a lower effective concentration (approximately 10-fold lower than OTX015) and a higher selectivity toward BET, ABBV-075 led to DLTs. Consistent with previous clinical trials on BETis, thrombocytopenia, gastrointestinal effects and hypertension were among the most common adverse events, which all were reversible. Since no selective BETis have entered clinical trials, it is difficult to foresee their outcome. It is expected that selective BETis would maintain their efficacy, but minimise the side effects [63]. To explore the individual functional contributions of BD1 and BD2 in biology and therapy, selective BD1 and BD2 inhibitors have been developed: GSK778 and GSK046 (termed iBET-BD1 and iBET-BD2, respectively) [63]. iBET-BD1 phenocopies the effects of pan-BET inhibitors in cancer models, whereas iBET-BD2 is predominantly effective in inflammatory and autoimmune disease models.
Table 1. BET inhibitors in clinical trials.

| Compound     | Target          | Combination | Tumour Type                                                                 | Results          | Phase/Status            | Reference       |
|--------------|-----------------|-------------|----------------------------------------------------------------------------|------------------|-------------------------|-----------------|
| ABBV-075     | BRD2/4, BRDT    | N/A         | Solid tumours: BC, CRC, PR, PrC, uveal melanoma, head and neck               | SD: 26<br>\(n = 71\) | I, completed            | NCT02391480     |
| Venetoclax   |                 |             |                                                                             | CR: 3<br>PR: 2<br>MLFS: 2<br>\(n = 44\) |                         | [64]            |
| Navitocla xRuxolitinib | MF       | Not posted   | I, not yet recruiting                                                      |                 | NCT04480086           |
| ABBV-744     | BRD2/3/4, BRDT  | N/A         | AML                                                                        | Not posted       | I, terminated           | NCT03360006     |
| Navitocla xRuxolitinib | MF       | Not posted   | I, recruiting                                                              |                 | NCT04454658           |
| BAY1238097   | BRD4            | N/A         | Solid tumours, myeloma, lymphoma                                            | NR: 8<br>SD: 2<br>\(n = 11\) | I, terminated          | NCT02369029     |
| BI 894999    | BRD2/3/4, BRDT  | N/A         | Solid tumours and lymphoma                                                  | Not posted       | I, not yet recruiting   | NCT02516553     |
| BMS-986158   | Undisclosed     | N/A         | Solid tumours and lymphoma in children                                      | Not posted       | I, recruiting           | NCT03936465     |
| Nivolumab    |                 |             | Advanced solid tumours and haematological malignancies                     | Not posted       | I/II, not yet recruiting| NCT02419417     |
| CC-90010     | Undisclosed     | N/A         | Solid tumours and NHL                                                       | Not posted       | I, recruiting           | NCT03220347     |
| CPI-0610     | BRD4            | N/A         | Lymphoma                                                                   | CR: 2<br>PR: 3<br>SD: 5<br>\(n = 64\) | I, completed          | NCT01949883     |
|              |                 | N/A         | MM                                                                         | Not posted       | I, completed            | NCT02157636     |


| Compound | Target | Combination | Tumour Type | Results | Phase/Status | Reference |
|----------|--------|-------------|-------------|---------|--------------|-----------|
| N/A      | Peripheral nerve tumours | Not posted | II, withdrawn | NCT02986919 |
| Ruxolitinib | MF | Not posted | I/II, recruiting | NCT02158858 |
| FT-1101 | BRD2/3/4, BRDT | Azacitidine | AML, MDS, NHL | Not posted | I, completed | NCT02543879 |
| GS-5829 | N/A | Solid tumours, lymphoma | Not posted | I, completed | NCT02392611 |
| Exemestane Fulvestrant | ER-positive BC | Not posted | | |
| Exemestane Fulvestrant | ER-positive and HER-negative BC | Not posted | I/II, terminated | NCT02983604 |
| Enzalutamide | Castrate-resistant PrC | Not posted | I/II, terminated | NCT02607228 |
| I-BET151 (GSK2820151) | BRD2/3/4 | N/A | Solid tumours | Not posted | I, terminated | NCT02630251 |
| I-BET762 (GSK525762) | BRD2/3/4, BRDT | N/A | Hematologic malignancies | Not posted | I/II, completed | NCT01943851 |
| N/A | NMC | PR: 2 SD: 7 $n = 19$ | I, completed | NCT01587703 [53,68] |
| Trametinib | Solid tumours | Not posted | I/II, withdrawn | NCT03266159 |
| Entinostat | Solid tumours and haematological malignancies | Not posted | I, withdrawn | NCT03925428 |
| INCB054329 | BRD2/3/4, BRDT | N/A | Solid tumours and haematological malignancies | Not posted | I/II, withdrawn | NCT02431260 |
| INCB057643 | BRD2/3/4 | Abiraterone, Azacitidine, Gemcitabine, Paclitaxel, Rucaparib, Ruxolitinib | Solid tumours | CR: 2 PR: 4 $n = 134$ | I/II, terminated | NCT02711137 [69] |
| Compound            | Target                        | Combination | Tumour Type                | Results                  | Phase/Status               | Reference       |
|---------------------|-------------------------------|-------------|----------------------------|--------------------------|---------------------------|-----------------|
| ODM-207             | Undisclosed                   | N/A         | Solid tumours              | SD: 6 $n = 27$           | I/II, completed           | NCT03035591     |
| OTX015 (MK-8628)    | BRD2/3/4                      | N/A         | AML, DLBCL                 | Not posted               | I, active, not recruiting | NCT02698189     |
|                     |                               | N/A         | CRPC, NMC, NSCLC, TNBC     | Not posted               | I, terminated             | NCT02698176     |
|                     |                               | N/A         | Glioblastoma multiforme    | PR: 3 (NMC) SD: 25 (3 NMC) $n = 46$ | II, terminated | NCT02296476     |
|                     |                               | N/A         | AML, acute lymphoblastic leukaemia, DLBCL, MM | CR:2 (DLBCL) PR:1 (DLBCL) $n = 33$ CR: 2 (AL) PR: 3 (AL) $n = 41$ | I, completed | NCT01713582     |
| Azacitidine         | AML                           | N/A         | Not posted                 | Not posted               | I/II, withdrawn           | NCT02303782     |
| PLX51107            | BRD2/3/4, BRDT                | N/A         | Solid tumours and haematological malignancies | Not posted               | I/II, terminated           | NCT02683395    |
| RO6870810 (TEN-010) | Undisclosed                   | N/A         | AML, MDS                   | CR: 1 SD: 13 $n = 32$    | I, completed              | NCT02308761     |
|                     |                               |             | Solid tumours              | PR: 1 (solid tumours) SD: 24 (solid tumours) $n = 47$ PR: 2 (NMC) SD: 5 (NMC) $n = 8$ PR: 2 (DLBCL) SD: 4 (DLBCL) $n = 19$ | I, completed | NCT01987362     |
Table 1. Cont.

| Compound                      | Target                | Combination        | Tumour Type         | Results   | Phase/Status     | Reference         |
|-------------------------------|-----------------------|--------------------|---------------------|-----------|------------------|-------------------|
| Venetoclax xRituximab         |                       | DLBCL, B-cell lymphoma | Not posted         | I, completed | NCT03255096     |
| ZEN-3694                      | Undisclosed           | N/A                | Metastatic CRPC     | Not posted | I, completed     | NCT02705469       |
| Enzalutamide                  |                       | Metastatic CRPC    | Not posted          | I/II, completed | NCT02711956 |
| Enzalutamide Pembrolizumab    |                       | Metastatic CRPC    | Not posted          | II, recruiting | NCT04471974 |
| Ipilimumab Nivolumab          |                       | Solid tumours      | Not posted          | I, not yet recruiting | NCT04840589 |

Abbreviations: AL, acute leukaemia; AML, acute myeloid leukaemia; CR, complete response; CRC, colorectal cancer; CRPC, castrate-resistant prostate cancer; DLBCL, diffuse large B-cell lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MLFS, morphological leukaemia-free state; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; NMC, NUT midline carcinoma; NR, no response; PC, pancreatic cancer; PR, partial response; SD, stable disease; TNBC, triple-negative breast cancer. Additional information: abiraterone (AR pathway inhibitor), azacitidine (DNMT inhibitor), entinostat (HDAC inhibitor), enzalutamide (AR inhibitor), exemestane (ER pathway inhibitor), fulvestrant (ER inhibitor), gemcitabine (cytostatic drug), ipilimumab (anti-CTLA-4 antibody), navitoclax (BCL2 inhibitor), nivolumab (PD-1 inhibitor), paclitaxel (cytostatic drug), pembrolizumab (anti-PD-1 antibody), rituximab (anti-CD20 antibody), rucaparib (PARP inhibitor), ruxolitinib (JAK inhibitor), trametinib (MEK inhibitor), venetoclax (BCL2 inhibitor).
6. Resistance to BET Inhibitors

The effectiveness of anticancer therapies can be limited by primary and acquired resistance [73]. Preclinical and clinical studies presented varying sensitivities of cancer cells to BETis, suggesting that drug resistance could, at least partially, contribute to this effect. Until now, the resistance to BETis has not been attributed to BRD2/3/4 mutations. Two studies indicated that the WNT signalling pathway is implicated in AML resistance to BETis [74,75]. Possible mechanisms of resistance to BETis encompass AMPK-ULK1-mediated autophagy in AML [76,77], NF-κB in colorectal cancer [78], PP2A phosphatase and BCL2L1/BCL-X in breast cancer [79], the GLI2-dependent Hedgehog pathway in pancreatic cancer [80] and kinome reprogramming in ovarian cancer [81], among others. Further studies demonstrated multiple mechanisms of resistance to BETis in solid tumours, including triple-negative breast cancer (TNBC), CRPC, and lung cancer [82–84]. The multitude of resistance mechanisms in diverse cancer models indicates that sensitivity to BETis might be cancer-cell-type-dependent. Further clinical studies, possibly in combination, will need to address this issue.

7. BET Inhibitors in Combination Therapy

Clinical studies demonstrated that BETis generally cause modest anticancer activity, predominantly due to the cytostatic effect, and evoke DLTs and adaptive resistance. BETi monotherapy can induce complete remission in NMC and non-NMC cancer types, particularly in haematological cancers [47,51,55,85]. Considering that (1) these remissions are often short-lived, (2) primary and acquired resistance emerge and (3) DLTs arise, the combination of BETis with other conventional and targeted therapies can provide meaningful clinical benefits. Emerging data from preclinical studies revealed that BETis have improved activity when used in combination therapy. In addition, BETis have been synergised with different classes of compounds in various tumour types, including solid tumours and haematologic malignancies (Table 2) [49]. Combinatorial treatment with molecularly targeted agents such as inhibitors of phosphoinositide 3-kinase (PI3K), extracellular signal-regulated kinases (ERK) and poly(ADP-ribose)polymerase (PARP) was beneficial. Strong synergy has been observed with histone deacetylase HDAC inhibitors (HDACis) in solid tumours and haematologic malignancies, indicating that this combination could be generalisable. A benefit has been seen when combining BETis with kinase inhibitors, including ALK, BTK, CDK, PLK1, JAK2 and PIKK. Since BETis generally induce a cytostatic effect, their complementation with apoptotic triggers, such as BCL-2 inhibitors, proved successful, and several clinical trials evaluated their efficacy. Additionally, BETis demonstrated synergistic activity in combination with immune system modulators, chemotherapeutics, hormone therapeutics and other epigenetic drugs. Some of the combinations mentioned above are discussed below.

Large-scale combinatorial screening with BETis and ~1900 compounds from the Mechanism Interrogation PlatE (MIPE) library in two MYC-amplified neuroblastoma cell lines identified PI3K inhibitors among the most synergistic combinations [86]. This combination was validated in a diverse panel of neuroblastoma cell lines and in vivo, including a patient-derived xenograft mouse model of MYCN-amplified neuroblastoma. Moreover, the combination of BETis and PI3K inhibitors proved effective in various cancer types (Table 2). Several studies reported that inhibition of the PI3K pathway could overcome the primary and acquired resistance to BETis [81,86]. Among the downstream effectors of the PI3K pathway is mTOR, which regulates cell growth, proliferation and survival [87]. BETis and mTOR inhibitors combined resulted in a synergistic antitumour effect in vitro and in vivo (Table 2). This combination proved successful in a diverse panel of cancer cells, including breast cancer, glioblastoma, lymphoma and osteosarcoma, suggesting that this is worth being further evaluated as cancer-type-independent treatment. The MEK-ERK signalling pathway intertwines with the PI3K-mTOR pathway, and alterations in both signalling pathways are frequently observed in cancer cells [88]. Gene expression
profiling revealed that the MEK-ERK pathway was upregulated after BETi treatment, suggesting its participation in acquired resistance [89]. Indeed, the combination of BETis and MEK-ERK inhibitors predominantly exhibits synergy in most cancer cell lines of various origins (Table 2).

It is well accepted that epigenetic status is already widely altered at the cancer initiation stage [90]. Given the importance of epigenetic changes in carcinogenesis, epigenome-targeted therapy has been considered a promising strategy for anticancer treatment. The efficiency of anticancer treatment is generally higher when epigenome-oriented drugs are applied in combination than as a monotherapy. Histone acetylation is a dynamic and reversible process that makes it a high-priority therapeutic target. HDACs regulate the level of acetylation of lysine residues on histone tails, and HDACis are potent agents that disrupt this modification and are used clinically in anticancer treatment. Several studies have reported the increased efficacy of HDAC and BET dual inhibition in cancer cells (Table 2). HDACis and BETis have similar antitumorigenic effects, e.g., HDACis suppresses MYC expression and its target genes [91]. The synergistic effect of combined HDACi and BETi treatment is challenging to explain since HDACis would be expected to increase global histone acetylation levels, thus providing a platform for BET binding, whereas BETis would prevent BET–chromatin interaction [92]. HDACis were shown to have variable activity depending on the genomic region. HDACis have limited activity at promoters, whereas a robust change in acetylation was observed at gene bodies. It was suggested that HDACis might redistribute BET from promoters and enhancers toward gene bodies. The suppression of chromatin interaction with BET would explain the similar cellular effects evoked by HDACis and BETis and the synergistic effect of their combination. A mechanistic study revealed that the cytotoxic effect induced by the cotreatment with JQ1 and HDACi was attributed to the induction of DNA damage and impaired DNA repair through the suppression of RAD51, a key homologous recombination (HR) protein [93]. The ectopic expression of RAD51 partially compromised the cytotoxic effect elicited by the cotreatment with JQ1 and HDACi, indicating that RAD51 downregulation could be significant for clinical benefit. The strong synergy between HDACis and BETis in several cancer cells motivated the design and synthesis of dual BET/HDAC inhibitors (reviewed in [94]). Similar to dual BET/HDAC inhibitors, other single-molecule cotargeting BET and cancer key drivers have been reported, including dual PI3K/BET, CDK/BET, JAK2/BET, PLK1/BET and EGFR/BET inhibitors (reviewed in [95]). Recently, the multitarget inhibition of CDK4/6-PI3K-BET with a rationally designed compound SRX3177 demonstrated broad cytotoxic activity against various cancer types [96].
A drug combination screen of 20 well-characterised drugs targeting seven classes of epigenetic regulators identified a strong synergy between BETis and PARP inhibitors (PARPis) [35]. PARPis have been extensively used to evoke synthetic lethality in cells with inefficient HR, primarily due to germline loss-of-function mutations in either BRCA1 or BRCA2 in breast, ovarian, prostate and pancreatic cancers [97,98]. PARPis target PARP1 and PARP2, which are necessary sensors of DNA damage that recognise single-stranded breaks (SSBs) and transduce the signal in the DDR pathway. Mechanistically, blocking PARP1’s enzymatic activity compromises the repair of SSBs, which become converted to double-stranded breaks (DSBs) during DNA replication, thus inducing synthetic lethality in cancer cells with deficient HR. BETis caused epigenetic loss of BRCA1 expression in BRCA1 wild-type TNBC cells and synergised with PARPis impairing HR and thus triggering synthetic lethality [99]. The independence from intrinsic HR status is consistent with the BETi-induced deficiency in HR. Simultaneous inhibition of BET and PARP could expand the spectrum of cancer types qualifying for PARPi treatment beyond those with deficient HR [35,100,101].

Moreover, BETis reversed multiple mechanisms of acquired PARPi resistance, which frequently develops in patients [100]. The effects of PARPi and BRD4i combinations were observed in numerous cancer lineages, suggesting that the synergistic activity is likely to be generalisable. The synergistic effect of BETi and PARPi was attributed directly to the loss of BET and PARP1, as synergy was confirmed when four different BETis were applied or when PARP1 was knocked down. Furthermore, the synergy with PARPis was noted with BRD4 knockdown, but not with BRD2 or BRD3. The synergistic effect of BETis and PARPis was attributed to CtIP’s (an HR pathway protein) decreased transcription since forced expression of CtIP, but not BRCA1 or RAD52, rescued cells from the synergistic effect of these inhibitors.
Table 2. Combinations of BET inhibitors with anticancer drugs in preclinical tumour models and clinical trials.

| Classes of Compounds                  | Compounds             | Preclinical Study | Clinical Trial                  |
|---------------------------------------|-----------------------|-------------------|---------------------------------|
|                                       |                       | Cancer References | Phase/Status Cancer References  |
| Small molecular weight inhibitors     | ALK inhibitors        | Lymphoma          | [57]                            |
|                                       |                       |                   |                                 |
|                                       | BTK inhibitors        | Lymphoma          | [57,89,100,102–107]             |
|                                       |                       |                   |                                 |
|                                       | CDK inhibitors        | Lymphoma          | [105,106]                       |
|                                       |                       | Osteosarcoma      | [108]                           |
|                                       |                       |                   |                                 |
| Advanced solid tumours and haematological malignancies | BCL2/MCL1 inhibitors | ALL               | [109]                           |
|                                       |                       | AML               | [62,64,110]                     |
|                                       |                       | LC                | [111]                           |
|                                       |                       | Lymphoma          | [105,106,112–114]               |
|                                       |                       |                   | I, recruiting MF                |
|                                       |                       |                   | Advanced solid tumours and haematological malignancies | NCT02391480 |
|                                       |                       |                   |                                 |
|                                       | EGFR/ERBB2 inhibitors | BC                | [115]                           |
|                                       |                       | AML               | [116]                           |
|                                       |                       |                   |                                 |
|                                       | Hedgehog inhibitors   | Lymphoma          | [117]                           |
|                                       |                       |                   |                                 |
|                                       | JAK inhibitors        | AML               | [118]                           |
|                                       |                       | MF                | [66,67]                         |
|                                       |                       |                   | I, II, recruiting MF            |
|                                       |                       |                   |                                   |
|                                       | MEK/ERK inhibitors     | AML               | [119]                           |
|                                       |                       | BC                | [119]                           |
|                                       |                       | CRC               | [119,120]                       |
|                                       |                       | Lymphoma          | [89]                            |
|                                       |                       | MM                | [119]                           |
|                                       |                       | Neuroblastoma     | [121]                           |
|                                       |                       | NSCLC             | [110]                           |
|                                       |                       | OC                | [81]                            |
|                                       |                       | PrC               | [119]                           |
|                                       |                       | Thyroid cancer    | [122]                           |
| Classes of Compounds | Compounds | Preclinical Study | Clinical Trial |
|----------------------|-----------|------------------|----------------|
|                      |           | Cancer | References | Phase/Status | Cancer | References |
| mTOR inhibitors      | BC        |        |           |             |        |           |
|                      | Glioblastoma | [123] |           |             |        |           |
|                      | Lymphoma  | [89,102–104,107] |             |             |        |           |
|                      | OS        | [125] |           |             |        |           |
| PARP inhibitors      | BC        | [99,100,126] | I/II, terminated | Solid tumours | NCT02711137 |
|                      | Bladder cancer | [100] |           |             |        |           |
|                      | Endometrial cancer | [100] |           |             |        |           |
|                      | LC        | [127] |           |             |        |           |
|                      | OC        | [35,100,101] |             |             |        |           |
|                      | PC        | [100] |           |             |        |           |
| PI3K inhibitors      | BC        | [81,126] |           |             |        |           |
|                      | CRC       | [126] |           |             |        |           |
|                      | Lymphoma  | [102,104,128] |             |             |        |           |
|                      | Glioblastoma | [126] |           |             |        |           |
|                      | OC        | [80,126] |           |             |        |           |
| PIKK inhibitors      | Lymphoma  | [129] |           |             |        |           |
| Proteasome inhibitors| MM        | [62,130] |           |             |        |           |
| Antibodies           | Anti-CD20 monoclonal antibodies | Lymphoma | [104,107,131] |             |        |           |
| Immune modulators    | Immunomodulatory drugs (IMiDs) | Lymphoma | [89,104,132,133] |             |        |           |
|                      | MM        | [134] |           |             |        |           |
| Anti-PD-1 monoclonal antibodies | Lymphoma | [135] | I/II, not yet recruiting | Solid tumours and haematological malignancies | NCT02419417 |
|                      |          | II, recruiting |             | Metastatic CRPC | NCT04471974 |
|                      |          | I, not yet recruiting |             | Solid tumours | NCT04840589 |
|                      |          | I/II, active, not recruiting, |             | Advanced tumours | NCT02419417 |
| Anti-4-1BB monoclonal antibodies | Lymphoma | [135] |             |             |        |           |
| Chimeric antigen receptor (CAR) T-cells | Lymphoma | [135] |             |             |        |           |
|                      |          | ALL    | [136] |             |        |           |
Table 2. Cont.

| Classes of Compounds | Compounds          | Preclinical Study | Clinical Trial                      |
|----------------------|--------------------|-------------------|-------------------------------------|
|                      |                    | Cancer References | Phase/Status                        | Cancer                              | References |
| Epigenetic drugs     | EZH2 inhibitors    | Lymphoma          | [103,137]                           | Advanced and refractory solid tumours and lymphomas | NCT03925428 |
| HDAC inhibitors      | AML                | [116]             | I/II withdrawn                      |                                      |            |
|                      | Bladder cancer     | [138,139]         |                                     |                                      |            |
|                      | BC                 | [140]             |                                     |                                      |            |
|                      | Chondrosarcoma     | [93]              |                                     |                                      |            |
|                      | Glioblastoma       | [141]             |                                     |                                      |            |
|                      | LC                 | [142]             |                                     |                                      |            |
|                      | Lymphoma           | [57,104,106,107,113,143–145] | I/II completed | Haematological malignancies | NCT02303782 |
|                      | Melanoma           | [146]             | I/II, terminated                    | Solid tumours                        | NCT02543879 |
|                      | Neuroblastoma      | [147]             |                                      |                                      | NCT02711137 |
|                      | PC                 | [148–150]         |                                      |                                      |            |
|                      | Sarcoma            | [151]             |                                      |                                      |            |
| Azacytidine          | AML                | [62]              | I/II, withdrawn                     | AML                                 | NCT02303782 |
|                      |                    |                   | I/II completed                      | Haematological malignancies         | NCT02543879 |
|                      |                    |                   | I/II, terminated                    | Solid tumours                       | NCT02711137 |
| Decitabine           | Lymphoma           | [104]             |                                      |                                      |            |
| Chemotherapy         | Gemcitabine        |                   | I/II, terminated                    | Solid tumours                       | NCT02711137 |
|                      | Paclitaxel         |                   | I/II, terminated                    | Solid tumours                       | NCT02711137 |
|                      | Temozolomide       |                   |                                      |                                      |            |
|                      | Glioblastoma [124] |                   |                                      |                                      |            |
| Hormone therapy      | Antiandrogen       | PrC [152]         | I/II, active, completed             | PrC                                 | NCT02711956 |
|                      |                    |                   | II, recruiting                      | PrC                                 | NCT04471974 |
|                      |                    |                   | I/II, terminated                    | PrC                                 | NCT02607228 |
|                      |                    |                   | I/II, terminated                    | Solid tumours                       | NCT02711137 |
| Estrogen receptor    | BC [153]           | I, completed      |                                      | BC                                  | NCT02392611 |
| degrader             |                    |                   |                                      | I/II, terminated                    | NCT02983604 |

Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BC, breast cancer; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; LC, lung cancer; MF, myelofibrosis; MM, multiple myeloma; OC, ovarian cancer; PC, pancreatic cancer; PrC, prostate cancer.
8. BET in DNA Repair

As mentioned earlier, the anticancer activity of BETis could not be merely explained by their influence on the transcription of cancer driver genes, such as MYC. The promising preclinical studies on the combinatorial treatment of BETis and PARPis triggering synthetic lethality in cancer cell lines of various origin imply that suppression of DNA repair efficacy could be an essential mechanism of BETis’ anticancer effect.

Alterations in DDR can lead to the accumulation of DNA damage, which is one of the main drivers of cancer progression. Moreover, insufficient DNA repair can contribute to cancer aggressiveness and can facilitate the emergence of resistance to anticancer DNA-damaging drugs [154]. Although DNA damage is a causal factor for carcinogenesis, it can be utilised in favour of anticancer treatment. Evidence indicates that inhibitors of DNA repair pathways can work as single agents for the targeted treatment of DNA repair-defective cancers [97,98]. The inhibitors of DNA damage repair target fast-replicating cells; thus, they could prove selective for cancer cells and have fewer side effects. DNA damage misrepaired or left unrepaired could persist into the S-phase of the cell cycle and result in a stalled replication fork, leading to the formation of replication-associated DSBs, generally considered to be one of the most deleterious DNA lesions. DSBs are repaired by a few DNA repair pathways, mainly HR—which requires the presence of complementary strand and thus acting in the S and G2 cell cycle phases—and non-homologous end joining (NHEJ)—which involves microhomology and is active in each cell cycle phase. The NHEJ pathway can introduce small insertions or deletions that frequently manifest as missense or frameshift mutations after repair. Apart from the principal HR and NHEJ pathways, DSBs can also be repaired by highly mutagenic alternative end-joining (alt-EJ) (also known as microhomology-mediated end joining, MMEJ), single-stranded annealing (SSA), synthesis-dependent strand annealing (SDSA) and break-induced repair (BIR). Despite the specificity of each pathway for particular DNA damage and cell cycle phase, none of them is mutually exclusive, and they form a network that involves proteins determining the repair outcomes.

Mechanistic studies have revealed that BET proteins play a role in DSB repair via modulating HR, which could be beneficial for anticancer treatment (Figure 3). A first notion of the role of BET in HR repair came from the three independent studies on BETis, JQ1 and GSK525762A [35,99,100]. These studies showed that BETis inhibited BRD2/3/4 and BRDT and consequently decreased HR repair efficiency. These results were further confirmed by the pooled siRNAs targeting BRD2, BRD3 and BRD4, ensuring that BET proteins participate in HR repair [35]. Although Mio et al. and Sun et al. studied only the influence of BRD4, the research conducted by Yang et al. in 2017 demonstrated that the inhibition of each BRD2/3/4 disrupted HR.

Further analyses indicated that JQ1 impaired HR by decreasing the foci formation of BRCA1 and RAD51 in irradiated cells [35,99]. This effect was accompanied by a reduction of the mRNA and protein expression of BRCA1 and RAD51 for individual siRNAs targeting BRD2/3/4. However, it was the most prominent for pooled siRNA, indicating BET’s joint participation in transcriptional repression [35]. The importance of BET-mediated regulation of BRCA1 and RAD51 expression in carcinogenesis should be emphasised because their expression was repressed by BETis to a comparable extent as MYC repression in multiple cancer models. BRCA1 and RAD51 colocalise at nuclear foci [155] and interact with each other to provide key steps of HR. BRCA1 participates in DNA end resection, providing single-strand DNA (ssDNA), a prerequisite and determinant step for HR. After the generation of ssDNA, BRCA1 recruits other proteins, including RAD51, to DSB sites. RAD51 is a recombinase that forms filaments with ssDNA to conduct homology search and strand invasion [156]. A recent study demonstrated that BRCA1 stimulates the recombinase activity of RAD51 and promotes RAD51-mediated pairing of homologous sequences [157]. Considering the critical role of BET proteins in gene transcription, the effect of BETis on the transcription of BRCA1 and RAD51 was investigated. A mechanistic study revealed that JQ1 repressed the expression of BRCA1 and RAD51 by reducing the recruitment of BRD2/3/4 to their promoter regions [35,99]. Furthermore, a super-enhancer region in
the BRCA1 gene was identified [35]. It was shown that this BET-sensitive super-enhancer region physically interacts with the BRCA1 promoter, influencing BRCA1 expression.

Figure 3. The role of bromodomain and extraterminal domain (BET) proteins in DNA damage response (DDR). DNA double-stranded breaks (DSB) are recognized by the MRN complex (NBS1, MRE11 and RAD50) and ATM/ATR kinases, followed by H2AX phosphorylation and activation of CHK1/CHK2 kinases, leading to diverse cellular responses, including cell cycle arrest and DNA repair. DSBs are mainly repaired through homologous recombination (HR), a multistep process encompassing DNA damage recognition, DNA end resection, strand invasion, repair synthesis and end ligation. BET controls key HR proteins’ transcription: BRCA1, RAD51 and CtIP, through interaction with their promoter regions. BRCA1, BRCA2, BRIP1, CtIP, FANCD2, CHK1, CHK2, MRE11, RAD50, RAD51, TIP60 and WEE1 expression is sensitive to BET inhibitors (BETis).

On the other hand, Sun et al. demonstrated that four different BETis decreased the expression of essential DNA repair genes, among which CtIP was the most suppressed [100]. Among all deregulated DNA repair proteins, CtIP was strongly and consistently downregulated under all conditions, while the effects of BETis on RAD51 and BRCA1 were modest and variable. Moreover, JQ1 repressed BRD4 binding to the CtIP promoter and enhancer and decreased the association of Pol II with these sequences. CtIP is an endonuclease that cooperates with the MRE11-RAD50-NBN (MRN) complex in DNA end resection. Its
BETi-mediated downregulation was sufficient to impair HR function. The overexpression of CtIP, but not RAD51 or BRCA1, partially rescued BRD4-inhibition-induced defects in DNA end resection and HR.

Apart from repressing BRCA1, RAD51 and CtIP expression, BETis downregulated the expression of HR proteins such as BRCA2, BRIPI, FANCD2, CHK1, CHK2, MRE11, RAD50, TIP60, WEE1 and EZH2 [89,93,99,100]. BRCA2 is the primary mediator of RAD51 nucleofilament formation and strand exchange in HR. BRIPI (FANCJ/BACH1) is a DEAH helicase that interacts with the BRCT domain of BRCA1 and plays a role in HR and the repair of crosslinks by the Fanconi anaemia pathway [158,159]. FANCD2 colocalises with BRCA1, BRCA2 and RAD51 nuclear foci and is involved in DSB and crosslinks repair [160–162]. CHK1/2 are kinases that orchestrate DDR [163]. MRE11 and RAD50 are components of the MRN complex, which together with CtIP participate in DNA resection in HR [164]. TIP60 is a HAT that regulates HR repair [165]. WEE1 is a checkpoint kinase that inhibits Cdc2, resulting in G2 arrest [166]. EZH2 is a histone-lysine N-methyltransferase that regulates the expression of BRCA1 and RAD51 [167]. Overall, these results indicate that BETis decrease HR. On the other hand, JQ1 treatment did not influence the expression of the Ku complex, which plays a crucial role in NHEJ. Additionally, JQ1 increased NHEJ efficiency, indicating that BETis switched the repair of DSB from HR to NHEJ [35]. Indeed, the comparative analysis demonstrated HR deficiency in cells with individual siRNA-mediated knockdown of BRD2/3/4, while NHEJ stayed intact [168]. On the other hand, BRD4 was critical for NHEJ in the class switch recombination (CSR) occurring in B-cells [169]. Moreover, JQ1 was sufficient to suppress CSR, indicating that NHEJ repair and CSR are directly dependent on the presence of BRD4.

Additionally, BETis directly influenced DDR by increasing the formation of γH2AX, a marker of DSBs (Figure 4) [25,93,100,168]. Specific depletion of BRDT, BRD2, BRD3 and BRD4 indicates that BRD2 and BRD4 knockdown increased DSBs levels, suggesting that cells deficient in these BETis are susceptible to spontaneous DSB formation [168]. Given that BET-deficient cells are characterised by altered transcription and elevated DSBs, the role of transcription in DNA damage induction was investigated. BRD2 and BRD4 inhibited the formation of transcription-associated RNA-DNA hybrids (R-loops). A mechanistic study revealed that BRD2 promoted topoisomerase I activity, a known restrainer of R-loops, thus explaining the increased R-loop formation and subsequent endogenous DSBs' induction observed in BRD2-deficient cells. Another mechanism that contributes to increased DNA damage formation in BETi-treated cells involves the role of BRD4. An isoform B of BRD4 was identified to recruit the condensin II complex, SMC2 and CAPD3, to the sites of acetylated regions of chromatin in response to DNA damage (Figure 5) [25]. BRD4-mediated chromatin condensation resulted in DDR attenuation. BETis reversed this process leading to a more open chromatin structure that facilitates γH2AX foci formation.

Besides γH2AX, BET proteins interacts with other critical DNA-damage-signalling proteins. The DDR signalling pathway is orchestrated by the ATM and ATR kinases, which recognise DNA damage and activate downstream kinases. The second wave of phosphorylation is conducted by Chk1 and Chk2, predominantly via the ATM-Chk2 and ATR-Chk1 cascades. BETis synergise with ATR and Chk1 inhibitors in MYC-dependent lymphoma cells and are associated with increased DSBs and the induction of apoptosis [89,129].
BRD4-mediated chromatin condensation resulted in DDR attenuation. BETis reversed this process leading to a more open chromatin structure that facilitates γH2AX foci formation.

Figure 4. Bromodomain and extraterminal domain 2 and 4 (BRD2 and BRD4) proteins prevent DNA damage induction at the sites of RNA polymerase II (RNA Pol II) activity. BRD2 and BRD4 restrict the formation of transcription-associated DNA:RNA hybrids (R-loops). Topoisomerase I (TOP1) activity, a known restrainer of R-loops, is promoted by BRD2. R-loop formation leads to the exposure of a single-strand DNA (ssDNA) on the nontemplate strand to DNA damaging factors. This can result in the induction of single-stranded breaks (SSBs), which can be converted to double-stranded breaks (DSBs).
Figure 5. An isoform B of bromodomain and the extraterminal domain 4 (BRD4) protein participates in the persistence of DNA damage. (A) BRD4 binds acetylated histones in the open chromatin regions. Upon DNA damage, BRD4 recruits the condensin II complex consisting of SMC2 and CAPD3 to acetylated chromatin, resulting in chromatin compaction, attenuation of DNA repair and the persistence of DNA damage. (B) In the absence of BRD4, the chromatin remains open, allowing for DNA repair upon DNA damage.

9. Conclusions and Future Perspectives

Recent recognition of the role of transcriptional deregulation in cancer initiation and progression has led to the appreciation of transcriptional apparatus inhibitors [170]. Dysregulation of gene expression programs in cancer cells can occur through dysregulation of oncogenic master transcription factors, dysregulation of signalling and dysregulation of a transcriptional amplifier, such as MYC. Given that most human cancers exhibit genetic amplification or transcriptional dysregulation of MYC, the pharmacologic inhibition of MYC has been highly anticipated. MYC’s direct pharmacologic inhibition is challenging because transcription factor oncoproteins have been mainly refractory to conventional drug discovery approaches. Hitherto “undruggable” MYC has been indirectly targeted through the inhibition of BET, which are epigenome-regulating factors.

Eleven years have passed since the synthesis and biological evaluation of the first BETi, JQ1. Several BETis underwent ~35 ongoing or completed clinical trials during this period, while many others are currently in the drug development program. BETis have been tested mostly against MYC-dependent cancers, including hematologic malignancies such as B-cell lymphoma, AML, MM and solid tumours, such as brain, colorectal, lung, prostate and breast cancers. The anticancer properties seem to reflect the inhibition of BETi-mediated regulation of MYC expression. Contrary to the above mechanism of action, MYC-independent sensitivity to BETis was reported, suggesting that BETis target other proteins crucial for carcinogenesis [108,171].
Unfortunately, despite extensive preclinical and clinical evaluation, none of the BETis has yet received regulatory approval. Apart from NMC, no predictive biomarker has been identified so far, indicating that these trials are not targeting specific molecular subtypes (reviewed in [54]). Predictive biomarkers are essential for (1) selecting patients with the characteristics of inhibitor sensitivity, (2) verifying target inhibition and (3) understanding resistance mechanisms [172]. The lack of a biological rationale for BETi-oriented anticancer therapy hinders the introduction of BETis into regular clinical practice.

The advances in the development of specific BETis have drawn attention in medicinal chemistry as much as the identification of predictive biomarkers is crucial in molecular oncology. The emphasis is now on the design of selective inhibitors targeting either BET or BD1—a domain whose inhibition has demonstrated anticancer potential.

Based on the conducted clinical trials, it seems that BETis might rather be exploited in targeted therapies in selective cancer types than in conventional chemotherapy [173]. Clinical activity has been observed in NMC, haematological malignancies, including MM, AML, lymphomas and MLL, and solid tumours such as TNBC and CRPR, nonsmall-cell lung carcinoma or glioblastoma. Concerns about applying BETis in patients focus on their ability to specifically target cancer cells without affecting the homeostasis of normal cells. BETis primarily affect the epigenome landscape and thus the expression of transcription factors, including MYC. Although inhibition of transcription factors is presumed to act widely on numerous genes, it can exert highly selective effects on gene expression control [170]. Targeting tissue-specific master transcription factors in cancer, such as the oestrogen receptor, progesterone receptor and androgen receptor, has profound clinical benefit in treating hormone-dependent breast and prostate cancer. However, the knowledge of the clinical outcome of a few transcription factors cannot be directly translated to all transcription factors as the knowledge of tissue-specific master transcription factors remains limited. Other than BETis, epigenome-targeting drugs, such as HDACis, have been approved by the U.S. Food and Drug Administration (FDA) for oncological indications, raising hope that epigenetic drugs could be successfully used in anticancer treatment.

Multiple resistance mechanisms and DLTs further limit BETis’ efficacy, demonstrating the need for the use of BETis in combination therapy. The improved anticancer efficacy of BETis was noted in combination with different classes of compounds. Among them, the combination with inhibitors of DNA repair has been promising in preclinical evaluation. BETis induce HR deficiency through multiple mechanisms, including downregulation of RAD51, BRCA1 and CtIP, presumably via binding to their promoter regions. Additionally, these HR pathway proteins are dependent on MYC, which binds to the promoters of several HR pathway genes and transcriptionally regulates multiple components of the HR repair pathway, suggesting that BETis might have therapeutic potential suppressing HR directly and indirectly [174–178]. The dual inhibition of BETis and PARPis demonstrated synthetic lethality. Hopefully, as a few PARPis have received FDA approval so far, with a high probability, more approvals are coming.

In conclusion, BETis have potential as anticancer drugs; however, their clinical progress faces significant obstacles. It is expected that the advances in the development of next-generation compounds, the identification of predictive biomarkers and combination therapy will allow for BETis regulatory approval. Undoubtedly, research on BETis will contribute to a greater understanding of cancer biology, genomics and epigenomics.

Author Contributions: The manuscript was written by J.S. and P.T. P.T. provided critical revision of the manuscript. P.T. supervised the conception and design of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All important data is included in the manuscript.
Acknowledgments: All figures were created with BioRender.com.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hnisz, D.; Abraham, B.; Lee, T.L.; Lau, A.; Saint-Andréé, V.; Sigova, A.A.; Hoke, H.A.; Young, R.A. Super-Enhancers in the Control of Cell Identity and Disease. *Cell* 2013, **155**, 934–947. [CrossRef]
2. Whyte, W.A.; Orlando, D.A.; Hnisz, D.; Abraham, B.; Lin, C.Y.; Kagey, M.H.; Rahl, P.B.; Lee, T.L.; Young, R.A. Master Transcription Factors and Mediators Establish Super-Enhancers at Key Cell Identity Genes. *Cell* 2013, **153**, 307–319. [CrossRef]
3. Lovén, J.; Hoke, H.A.; Lin, C.Y.; Lau, A.; Orlando, D.A.; Vakoc, C.R.; Bradner, J.E.; Lee, T.L.; Young, R.A. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. *Cell* 2013, **153**, 320–334. [CrossRef] [PubMed]
4. Wu, S.-Y.; Chiang, C.-M. The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation. *J. Biol. Chem.* 2007, **282**, 13141–13145. [CrossRef] [PubMed]
5. Florence, B. You bet-cha: A novel family of transcriptional regulators. *Front. Biosci.* 2001, **6**, D1008–D1018. [CrossRef] [PubMed]
6. Belkina, A.; Denis, G.V. BET domain co-regulators in obesity, inflammation and cancer. *Nat. Rev. Cancer* 2012, **12**, 465–477. [CrossRef] [PubMed]
7. Dhar, S.; Thota, A.; Rao, M.R.S. Insights into Role of Bromodomain, Testis-specific (Brdt) in Acetylated Histone H4-dependent Chromatin Remodeling in Mammalian Spermiogenesis. *J. Biol. Chem.* 2012, **287**, 6387–6405. [CrossRef]
8. Pivot-Pajot, C.; Caron, C.; Govin, J.; Vion, A.; Rousseaux, S.; Khochbin, S. Acetylation-Dependent Chromatin Reorganization by BRDT, a Testis-Specific Bromodomain-Containing Protein. *Mol. Cell. Biol.* 2003, **23**, 5354–5365. [CrossRef]
9. Rahman, S.; Sowa, M.E.; Ottinger, M.; Smith, J.A.; Shi, Y.; Harper, J.W.; Howley, P.M. The Brd4 Extraterminal Domain Confers Transcription Activation Independent of P-TEFb by Recruiting Multiple Proteins, Including NSD. *Mol. Cell. Biol.* 2011, **31**, 2641–2652. [CrossRef]
10. Shen, C.; Iparso, J.; Shi, J.; Milazzo, J.P.; Wang, E.; Roe, J.-S.; Suzuki, Y.; Pappin, D.J.; Joshua-Tor, L.; Vakoc, C.R. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. *Mol. Cell* 2015, **60**, 847–859. [CrossRef]
11. Zhang, Q.; Zeng, L.; Shen, C.; Ju, Y.; Konuma, T.; Zhao, C.; Vakoc, C.R.; Zhou, M.-M. Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD. *Structure* 2016, **24**, 1201–1208. [CrossRef]
12. Zaware, N.; Zhou, M.-M. Bromodomain biology and drug discovery. *Nat. Struct. Mol. Biol.* 2019, **26**, 870–879. [CrossRef]
13. Jiang, M.K.; Mochizuki, K.; Zhou, M.; Jeong, H.-S.; Brady, J.N.; Ozato, K. The Bromodomain Protein Brd4 Is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-Dependent Transcription. *Mol. Cell* 2005, **19**, 523–534. [CrossRef]
14. Yang, Z.; Yik, J.H.N.; Chen, R.; He, N.; Jiang, M.K.; Ozato, K.; Zhou, Q. Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd. *Mol. Cell* 2005, **19**, 535–545. [CrossRef]
15. Jiang, Y.W.; Vescambre, P.; Erdjument-Bromage, H.; Tempst, P.; Conaway, J.W.; Conaway, R.C.; Kornberg, R.D. Mammalian mediator of transcription and its possible role as an end-point of signal transduction pathways. *Proc. Natl. Acad. Sci. USA* 1998, **95**, 8538–8543. [CrossRef]
16. Denis, G.V.; McComb, M.E.; Faller, D.V.; Sinha, A.; Romesser, P.B.; Costello, C.E. Identification of Transcription Complexes that Contain the Double Bromodomain Protein Brd2 and Chromatin Remodeling Machines. *J. Proteome Res.* 2006, **5**, 502–511. [CrossRef]
17. LeRoy, G.; Rickards, B.; Flint, S. The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to Transcription. *Mol. Cell* 2008, **30**, 51–60. [CrossRef]
18. Sinha, A.; Faller, D.V.; Denis, G.V. Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. *Biochem. J.* 2005, **387**, 257–269. [CrossRef]
19. Denis, G.V.; Vaziri, C.; Guo, N.; Faller, U.V. RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. *Cell Growth Differ.* Mol. Biol. J. Am. Assoc. Cancer Res. 2000, 11, 417–424. [CrossRef]
20. Dai, J.; Zhou, S.; Ge, Q.; Qin, J.; Li, J.; Ju, H.; Cao, Y.; Zheng, M.; Li, C.; Gao, X.; et al. Recruitment of Brd3 and Brd4 to acetylated chromatin is essential for proinflammatory cytokine-induced matrix-degrading enzyme expression. *J. Orthop. Surg. Res.* 2019, **14**, 59. [CrossRef] [PubMed]
21. Lamonica, J.M.; Deng, W.; Kadauke, S.; Campbell, A.E.; Gamsjaeger, R.; Wang, H.; Cheng, Y.; Billin, A.; Hardison, R.; Mackay, J.; et al. Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes. *Proc. Natl. Acad. Sci. USA* 2011, **108**, E139–E168. [CrossRef] [PubMed]
22. Stonestrom, A.; Hsu, S.C.; Jahn, K.S.; Huang, P.; Keller, C.A.; Giardine, B.M.; Kadauke, S.; Campbell, A.E.; Evans, P.; Hardison, R.; et al. Functions of BET proteins in erythroid gene expression. *Blood* 2015, **125**, 2825–2834. [CrossRef] [PubMed]
23. Wang, F.; Liu, H.; Blanton, W.P.; Belkina, A.; LeBrasseur, N.; Denis, G.V. Brd2 disruption in mice causes severe obesity without Type 2 diabetes. *Biochem. J.* 2009, **425**, 71–85. [CrossRef]
24. Berkovits, B.D.; Wang, L.; Guarnieri, P.; Wolgemuth, D.J. The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids. *Nucleic Acids Res.* 2012, **40**, 7162–7175. [CrossRef]
25. Floyd, S.; Pacold, M.E.; Huang, Q.; Clarke, S.M.; Lam, F.C.; Cannell, I.; Bryson, B.D.; Rameseder, J.; Lee, M.; Blake, E.J.; et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. *Nat. Cell Biol.* 2013, **498**, 246–250. [CrossRef]
51. Bauer, D.E.; Mitchell, C.M.; Strait, K.M.; Lathan, C.S.; Stelow, E.B.; Lüer, S.C.; Muhammed, S.; Evans, A.G.; Sholl, L.M.; Rosai, J.; et al. Clinicopathologic Features and Long-term Outcomes of NUT Midline Carcinoma. *Clin. Cancer Res.* 2012, 18, 5773–5779. [CrossRef]

52. Levin, J.; Soria, J.-C.; Stathis, A.; Delord, J.-P.; Peters, S.; Awada, A.; Aftimos, P.G.; Bekradda, M.; Rezai, K.; Zeng, Z.; et al. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. *J. Clin. Oncol.* 2018, 36, 3007–3014. [CrossRef]

53. Piha-Paul, S.A.; Hann, C.L.; French, C.A.; Cousin, S.; Braña, I.; Cassier, P.A.; Moreno, V.; De Bono, J.S.; Harward, S.D.; Ferron-Brady, G.; et al. Phase 1 Study of Molibresib (GSK25762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. *JNCI J. Natl. Cancer Inst.* 2019, 4, pkz093. [CrossRef]

54. Shorstova, T.; Foulkes, W.D.; Witcher, M. Achieving clinical success with BET inhibitors as anti-cancer agents. *Br. J. Cancer* 2021, 124, 1478–1490. [CrossRef] [PubMed]

55. Berthon, C.; Raffoux, E.; Thomas, X.; Vey, N.; Gomez-Roca, C.; Yee, K.; Taussig, D.C.; Rezai, K.; Roumier, C.; Herait, P.; et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study. *Lancet Haematol.* 2016, 3, e186–e195. [CrossRef]

56. Bradbury, R.H.; Callis, R.; Carr, G.R.; Chen, H.; Clark, E.; Feron, L.; Glossop, S.; Graham, M.A.; Hattersley, M.; Jones, C.; et al. Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl-1,3-dimethyl-piperazin-2-one (AZD5153). *J. Med. Chem.* 2016, 59, 7801–7817. [CrossRef] [PubMed]

57. Rhyasen, G.W.; Hattersley, M.M.; Yao, Y.; Dulak, A.; Wang, W.; Petteruti, P.; Dale, I.L.; Boiko, S.; Cheung, T.; Zhang, J.; et al. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. *Mol. Cancer Ther.* 2016, 15, 2563–2574. [CrossRef] [PubMed]

58. Shen, G.; Chen, J.; Zhou, Y.; Wang, Z.; Ma, Z.; Xu, C.; Jiang, M. AZD5153 Inhibits Prostate Cancer Cell Growth In Vitro and In Vivo. *Cell. Physiol. Biochem.* 2018, 50, 798–809. [CrossRef]

59. Xu, K.; Chen, D.; Qian, D.; Zhang, S.; Zhang, Y.; Guo, S.; Ma, Z.; Wang, S. AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo. *Biochem. Biophys. Res. Commun.* 2018, 499, 531–537. [CrossRef]

60. Wang, J.S.-Z.; De Vita, S.; Karlix, J.L.; Cook, C.; Littlewood, G.M.; Moorthy, G.; Edlund, H.; Gabbrì, G.; Sachsenmeier, K.F.; et al. First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data. *J. Clin. Oncol.* 2019, 37, 3085. [CrossRef]

61. Postel-Vinay, S.; Herbschleb, K.; Massard, C.; Woodcock, V.; Soria, J.-C.; Walter, A.O.; Ewerton, F.; Poelman, M.; Benson, N.; Ocker, M.; et al. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY1238097: Emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. *Eur. J. Cancer* 2019, 109, 103–110. [CrossRef]

62. Bui, M.H.; Lin, X.; Albright, D.H.; Li, L.; Lam, L.T.; Fairve, E.J.; Warder, S.E.; Huang, X.; Wilcox, D.; Donawho, C.K.; et al. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies. *Cancer Res.* 2017, 77, 2976–2989. [CrossRef]

63. Gilan, O.; Rioja, I.; Knezevic, K.; Bell, M.J.; Yeung, M.M.; Harker, N.R.; Lam, E.Y.N.; Chung, C.-W.; Bamborough, P.; Petretich, M.; et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuneinflammation. *Science 2020*, 368, 387–394. [CrossRef]

64. Borthakur, G.; Odenike, O.; Aldoss, I.; Rizzieri, D.A.; Prebet, T.; Chen, C.; Popovic, R.; Modi, D.A.; Joshi, R.H.; Wolff, J.E.; et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. *Cancer 2021*, 127, 2943–2953. [CrossRef]

65. Blum, K.; Abramson, J.; Maris, M.; Flinn, I.; Goy, A.; Mertz, J.; Sims, R.; Garner, F.; Senderovizc, A.; Younes, A. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. *Ann. Oncol.* 2018, 29, ii87–ii99. [CrossRef]

66. Mascarenhas, J.O.; Rampal, R.K.; Kosiorek, H.E.; Bhave, R.; Hexner, E.; Wang, E.S.; Gerds, A.; Abboud, C.N.; Kremyanskaya, M.; Berenson, D.; et al. Phase 2 study of ruxolitinib and debatine in patients with myeloproliferative neoplasm in accelerated and blast phase. *Blood Adv.* 2020, 4, 5246–5256. [CrossRef]

67. Verstovsek, S.; Mascarenhas, J.; Kremyanskaya, M.; Hoffman, R.; Rampal, R.K.; Gupta, V.; Talpaz, M.; Granacher, N.; Leber, B.; Kiladjian, J.J.; et al. CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, as “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study. Available online: https://ash.confex.com/ash/2020/webprogram/Paper140891.html (accessed on 1 September 2021).

68. Parikh, S.A.; French, C.A.; Costello, B.A.; Marks, R.S.; Dronca, R.S.; Nerby, C.L.; Roden, A.C.; Peddareddigari, V.G.; Hilton, J.; Shapiro, G.J.; et al. NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm. *J. Thorac. Oncol.* 2013, 8, 1335–1338. [CrossRef] [PubMed]

69. Falchuk, G.; Rosen, S.; Lorusso, P.; Watts, J.; Gupta, S.; Coombs, C.C.; Talpaz, M.; Kurzrock, R.; Mita, M.; Cassaday, R.; et al. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. *Clin. Cancer Res.* 2020, 26, 1247–1257. [CrossRef] [PubMed]
70. Ameratunga, M.; Braña, I.; Bono, P.; Postel-Vinay, S.; Plummer, R.; Aspegren, J.; Korjamo, T.; Snapir, A.; de Bono, J.S. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br. J. Cancer 2020, 123, 1730–1736. [CrossRef]

71. Roboz, G.J.; Desai, P.; Lee, S.; Ritchie, E.K.; Winer, E.S.; DeMaria, M.; Brennan, B.; Nüesch, E.; Chesne, E.; Brennan, L.; et al. A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk. Lymphoma 2021, 62, 1740–1748. [CrossRef]

72. Shapiro, G.I.; LoRusso, P.; Dowlati, A.; Do, K.T.; Jacobson, C.A.; Vaishampayan, U.; Weise, A.; Caimi, P.F.; Eder, J.P.; French, C.A.; et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br. J. Cancer 2021, 124, 744–753. [CrossRef]

73. Settlemann, J. Bet on drug resistance. Nat. Cell Biol. 2016, 529, 289–290. [CrossRef] [PubMed]

74. Fong, C.Y.; Gilan, O.; Lam, E.Y.N.; Rubin, A.F.; Ftouni, S.; Tyler, D.; Stanley, K.; Sinha, D.; Yeh, P.; Morison, J.; et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 2015, 525, 538–542. [CrossRef] [PubMed]

75. Rathert, P.; Roth, M.; Neumann, T.; Muerdter, F.; Roe, J.-S.; Muhar, M.; Deswal, S.; Cerny-Reiterer, S.; Peter, B.; Jude, J.; et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nat. Cell Biol. 2015, 525, 543–547. [CrossRef] [PubMed]

76. Jang, J.E.; Eom, J.-I.; Jeung, H.-K.; Cheong, J.-W.; Lee, J.Y.; Kim, J.S.; Min, Y.H. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. Clin. Cancer Res. 2016, 23, 2781–2794. [CrossRef]

77. Jang, J.E.; Eom, J.-I.; Jeung, H.-K.; Cheong, J.-W.; Lee, J.Y.; Kim, J.S.; Min, Y.H. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. Autophagy 2017, 13, 761–762. [CrossRef]

78. Wu, T.; Wang, G.; Chen, W.; Zhu, Z.; Liu, Y.; Huang, Z.; Huang, Y.; Du, P.; Yang, Y.; Liu, C.-Y.; et al. Co-inhibition of BET proteins and NF-kB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Cell Death Dis. 2018, 9, 1–13. [CrossRef]

79. Shu, S.; Lin, C.Y.; He, H.H.; Witwicki, R.M.; Tabassum, D.P.; Roberts, J.; Janiszewska, M.; Huh, S.J.; Liang, Y.; Ryan, J.; et al. Resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nat. Cell Biol. 2016, 529, 413–417. [CrossRef] [PubMed]

80. Kumar, K.; Raza, S.S.; Knab, L.M.; Chow, C.R.; Kwok, B.; Bentrem, D.J.; Popovic, R.; Ebine, K.; Licht, J.D.; Munshi, H.G. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci. Rep. 2015, 5, 9489. [CrossRef]

81. Kurimchak, A.M.; Shelton, C.; Duncan, K.E.; Johnson, K.J.; Brown, J.; O’Brien, S.; Gabbasov, R.; Fink, L.S.; Li, Y.; Lounsbery, N.; et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep. 2016, 16, 1273–1286. [CrossRef]

82. Calder, J.; Nagelberg, A.; Luu, J.; Lu, D.; Lockwood, W.W. Resistance to BET inhibitors in lung adenocarcinoma is mediated by the casein kinase phosphorylation of BRD4. Oncogenesis 2021, 10, 27. [CrossRef] [PubMed]

83. Pawar, A.; Gollavilli, P.N.; Wang, S.; Asangani, I.A. Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Rep. 2018, 22, 2236–2245. [CrossRef]

84. Shu, S.; Wu, H.-J.; Ge, J.Y.; Zeid, R.; Harris, I.S.; Jovanović, B.; Murphy, K.; Wang, B.; Qiu, X.; Endress, J.E.; et al. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol. Cell Oncogenesis 2021, 32, 108638. [CrossRef] [PubMed]

85. Dawson, M.S.; Stein, E.M.; Huntly, B.J.P.; Karadimitris, A.; Kamdar, M.; Fernandez de Larrea, C.; Dickinson, M.J.; Yeh, P.S.H.; Daver, N.; Chaidos, A.; et al. A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML). Blood 2016, 138, 2236–2245. [CrossRef]

86. Iniguez, A.B.; Alexe, G.; Wang, E.J.; Roti, G.; Patel, S.; Chen, L.; Kitara, S.; Conway, A.; Robichaud, A.L.; Stolte, B.; et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell 2018, 34, 922–938.e7. [CrossRef]

87. Saxton, R.A.; Bateman, D.M. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017, 168, 960–976. [CrossRef] [PubMed]

88. Mendoza, M.C.; Er, E.E.; Blenis, J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem. Sci. 2011, 36, 320–328. [CrossRef]

89. Tarantelli, C.; Bernasconi, E.; Gaudio, E.; Cascione, L.; Restelli, V.; Arribas, A.; Spriano, F.; Rinaldi, A.; Mensah, A.A.; Kwee, I.; et al. BET bromodomain inhibitor birabresib in mantle cell lymphoma: In vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open 2018, 3, e000387. [CrossRef]

90. Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther. 2019, 4, 62. [CrossRef]

91. Slaughter, M.J.; Shanle, E.K.; Khan, A.; Chua, K.F.; Hong, T.; Boxer, L.D.; Allis, C.D.; Josefowicz, S.Z.; Garcia, B.A.; Rothbart, S.B.; et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 2021, 34, 108638. [CrossRef]
93. Huan, S.; Gui, T.; Xu, Q.; Zhuang, S.; Li, Z.; Shi, Y.; Lin, J.; Gong, B.; Miao, G.; Tam, M.; et al. Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair. *Cancer Manag. Res.* 2020, 12, 4429–4439. [CrossRef]

94. Ren, Q.; Gao, W. Current status in the discovery of dual BET/HDAC inhibitors. *Bioorg. Med. Chem. Lett.* 2021, 31, 127671. [CrossRef]

95. Carlini, L.; Rastelli, G. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. *J. Med. Chem.* 2016, 59, 9305–9320. [CrossRef]

96. Burgoyne, A.M.; Vann, K.R.; Joshi, S.; Morales, G.A.; Vega, F.M.; Singh, A.; Pal, D.; Merati, A.B.; Kutateladze, T.G.; Durden, D.L. A triple action CDK4/6-P13K-BET inhibitor with augmented cancer cell cytotoxicity. *Cell Discov.* 2020, 6, 1–4. [CrossRef][PubMed]

97. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmaina, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; Hubert, A.; et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. *J. Clin. Oncol.* 2015, 33, 244–250. [CrossRef]

98. Ashworth, A.; Lord, C.J. Synthetic lethal therapies for cancer: What’s next after PARP inhibitors? *Nat. Rev. Clin. Oncol.* 2018, 15, 564–576. [CrossRef]

99. Mio, C.; Gerratana, L.; Bolis, M.; Caponnetto, F.; Zanello, A.; Barbina, M.; Di Loreto, C.; Garattini, E.; Damante, G.; Puglisi, F. BET proteins regulate homologous recombination-mediated DNA repair: BRCAneus and implications for cancer therapy. *Int. J. Cancer* 2019, 144, 755–766. [CrossRef][PubMed]

100. Sun, C.; Yin, J.; Fang, Y.; Chen, J.; Jeong, K.J.; Chen, X.; Vellano, C.P.; Ju, Z.; Zhao, W.; Zhang, D.; et al. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. *Cancer Cell* 2018, 33, 401–416.e8. [CrossRef]

101. Wilson, A.J.; Stubbs, M.; Liu, P.; Ruggeri, B.; Khabele, D. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. *Gynecol. Oncol.* 2018, 149, 579–584. [CrossRef][PubMed]

102. Ceribelli, M.; Kelly, P.N.; Shaffer, A.L.; Wright, G.W.; Xiao, W.; Yang, Y.; Griner, L.A.M.; Guha, R.; Shinn, P.; Keller, J.M.; et al. Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. *Proc. Natl. Acad. Sci. USA* 2014, 111, 11365–11370. [CrossRef][PubMed]

103. Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Cacione, L.; Kwee, I.; Spriano, F.; Rinaldi, A.; Mensah, A.A.; Chung, E.; et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. *Br. J. Haematol.* 2017, 178, 936–948. [CrossRef][PubMed]

104. Boi, M.; Gaudio, E.; Bonetti, P.; Kwee, I.; Bernasconi, E.; Tarantelli, C.; Rinaldi, A.; Testoni, M.; Cacione, L.; Ponzoni, M.; et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. *Clin. Cancer Res.* 2015, 21, 1628–1638. [CrossRef]

105. Sun, B.; Fiskus, W.; Qian, Y.; Rajapakse, K.; Raina, K.; Coleman, K.G.; Crew, A.P.; Shen, A.; Saenz, D.T.; Mill, C.P.; et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. *Leukemia* 2017, 32, 343–352. [CrossRef]

106. Sun, B.; Shah, B.A.; Fiskus, W.; Qi, J.; Rajapakse, K.; Coarfa, C.; Li, L.; Devaraj, S.G.T.; Sharma, S.K.; Zhang, L.; et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. *Blood* 2015, 126, 1565–1574. [CrossRef]

107. Hientz, K.; Mohr, A.; Bhakta-Guha, D.; Efferth, T. The role of p53 in cancer drug resistance and targeted chemotherapy. *Oncotarget* 2017, 8, 8921–8946. [CrossRef]

108. Baker, E.K.; Taylor, S.; Gupte, A.; Sharp, P.; Walia, M.; Walsh, N.C.; Zannettino, A.; Chalk, A.; Burns, C.; Walkley, C.R. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. *Sci. Rep.* 2015, 5, 10120. [CrossRef]

109. Peirs, S.; Frismantas, V.; Matthijssens, F.; Van Loocke, W.; Pieters, T.; Vandamme, N.; Lintermans, B.; Dobay, M.P.; Berx, G.; Poppe, B.; et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. *Leukemia* 2017, 31, 2037–2047. [CrossRef]

110. Zhao, Y.; Liu, Q.; Acharya, P.; Stengel, K.; Sheng, Q.; Zhou, X.; Kwak, H.; Fischer, M.A.; Bradner, J.E.; Strickland, S.A.; et al. High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. *Cell Rep.* 2016, 16, 2003–2016. [CrossRef]

111. Lam, I.T.; Lin, X.; Faivre, E.J.; Yang, Z.; Huang, X.; Wilcox, D.M.; Bellin, R.; Jin, S.; Tahir, S.K.; Mitten, M.; et al. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors. *Mol. Cancer Ther.* 2017, 16, 1511–1520. [CrossRef]

112. Lasorsa, E.; Smonksey, M.; Kirk, J.S.; Rosario, S.; Hernandez-Illizaliturri, F.J.; Ellis, L. Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. *Cell Death Dis.* 2015, 6, e2014. [CrossRef]

113. Kim, S.R.; Lewis, J.M.; Cyrenne, B.M.; Monico, P.F.; Mirza, F.N.; Carlson, K.R.; Foss, F.M.; Girardi, M. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. *Oncotarget* 2018, 9, 29193–29207. [CrossRef]
114. Cummin, T.E.C.; Cox, K.L.; Murray, T.D.; Turaj, A.H.; Dunning, L.; English, V.L.; Fell, R.; Packham, G.; Ma, Y.; Powell, B.; et al. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. *Blood Adv.* 2020, 4, 3316–3328. [CrossRef]

115. Stuhlmiiller, T.J.; Miller, S.M.; Zawistowski, J.S.; Nakamura, K.; Beltran, A.S.; Duncan, J.S.; Angus, S.; Collins, K.A.; Granger, D.A.; Reuthe, R.A.; et al. Inhibition of Laptapin-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. *Cell Rep.* 2015, 11, 390–404. [CrossRef]

116. Fiskus, W.; Sharma, S.; Qi, J.; Shah, B.; Devaraj, S.G.T.; Leveque, C.; Portier, B.P.; Iyer, S.P.; Bradner, J.E.; Bhalla, K.N. BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. *Mol. Cancer Ther.* 2014, 13, 2315–2327. [CrossRef]

117. Picaud, S.; Wells, C.; Felletar, I.; Brotherton, D.; Martin, S.; Savitsky, P.; Diez-Dacal, B.; Philpott, M.; Bountra, C.; Lingard, H.; et al. BET Protein Antagonist JQ1 Synergizes with Rapamycin in Hematological Malignancies via Akt Inhibition. *Cancer Res.* 2013, 73, 2200–2209. [CrossRef]

118. Cummin, T.E.C.; Cox, K.L.; Murray, T.D.; Turaj, A.H.; Dunning, L.; English, V.L.; Fell, R.; Packham, G.; Ma, Y.; Powell, B.; et al. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. *Blood Adv.* 2020, 4, 3316–3328. [CrossRef]

119. Saenz, D.T.; Fiskus, W.; Qian, Y.; Manshouri, T.; Rajapakse, K.; Raina, K.; Coleman, K.G.; Crew, A.P.; Shen, A.; Mill, C.P.; et al. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETI) against post-myeloproliferative neoplasm secondary (s) AML cells. *Leukemia* 2017, 31, 1951–1961. [CrossRef]

120. Ma, Y.; Wang, L.; Neitzel, L.R.; Loganathan, S.N.; Tang, N.; Qin, L.; Crispi, E.E.; Guo, Y.; Knapp, S.; Beauchamp, R.D.; et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. *Oncotarget* 2017, 8, 7798–7813. [CrossRef]

121. Lee, J.R.; Hart, L.S.; Shazad, A.L.; Gagliardi, M.E.; Tsang, M.; Elias, J.; Ruden, J.; Farrel, A.; Rokita, J.L.; Li, Y.; et al. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. *Pediatr. Blood Cancer* 2020, 67, e28267. [CrossRef]

122. Zhu, X.; Holmsen, E.; Park, S.; Willingham, M.C.; Qi, J.; Cheng, S.-Y. Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. *Oncotarget* 2018, 9, 35408–35421. [CrossRef]

123. Vázquez, R.; Riveiro, M.E.; Astorgues-Xerri, L.; Odore, E.; Rezai, K.; Erba, E.; Panini, N.; Rinaldi, A.; Kwee, I.; Beltrame, L.; et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. *Oncotarget* 2017, 8, 7798–7813. [CrossRef]

124. Berenguer-Daizé, C.; Astorgues-Xerri, L.; Odore, E.; Cayol, M.; Cvitkovic, E.; Noel, K.; Bekradda, M.; MacKenzie, S.; Rezai, K.; Lokicé, F.; et al. OTX015 (MK-8628), a novel BET inhibitor, display s in vivo antitumor activity in triple-negative breast cancer models alone and in combination with conventional therapies in glioblastoma models. *Int. J. Cancer* 2016, 139, 2047–2055. [CrossRef]

125. Lee, D.H.; Qi, J.; Bradner, J.E.; Said, J.W.; Doan, N.B.; Forscher, C.; Yang, H.; Koeffler, H.P. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. *Int. J. Cancer* 2015, 136, 2055–2064. [CrossRef] [PubMed]

126. Stratikopoulos, E.E.; Dendy, M.; Szabolcs, M.; Khaykin, A.J.; Lefebvre, C.; Zhou, M.-M.; Parsons, R. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and OvercomeResistance to Therapy. *Cancer Cell* 2015, 27, 837–851. [CrossRef] [PubMed]

127. Fiorentino, F.P.; Marchesi, I.; Schröder, C.; Schmidt, R.; Yokota, J.; Bagella, L. BET-inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. *Int. J. Mol. Sci.* 2020, 21, 9595. [CrossRef] [PubMed]

128. Tinsley, S.; Meja, K.; Shepherd, C.; Khwaja, A. Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition. *Br. J. Haematol.* 2015, 170, 275–278. [CrossRef]

129. Muralidharan, S.V.; Bhadury, J.; Nilsson, L.M.; Green, L.C.; McLure, K.G.; Nilsson, J.A. BET bromodomain inhibitors synergize with conventional therapies in glioblastoma models. *Int. J. Cancer* 2016, 139, 2047–2055. [CrossRef] [PubMed]

130. Siegel, M.B.; Liu, S.Q.; Davare, M.; Spurgeon, S.E.; Loriaux, M.M.; Druker, B.; Scott, E.C.; Tyner, J.W. Small molecule inhibitor screen identifies synergetic activity of the bromodomain inhibitor CPI203 and zebrafish in drug resistant myeloma. *Oncotarget* 2015, 6, 18921–18932. [CrossRef]

131. Emadali, A.; Rousseaux, S.; Bruder-Costa, J.; Rome, C.; Duley, S.; Hamaida, S.; Betton, P.; Debernardi, A.; Leroux, D.; Bernay, B.; et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. *EMBO Mol. Med.* 2013, 5, 11102–11113. [CrossRef]

132. Gopalakrishnan, R.; Matta, H.; Tolani, B.; Triche, T., Jr.; Chaudhary, P.M. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cerebellum-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. *Oncogene* 2016, 35, 1797–1810. [CrossRef]

133. Moros, A.; Rodriguez, V.; Saborit-Villarroya, I.; Montraveta, A.; Balsas, P.; Sandy, P.; Martinez, A.; Wiestner, A.; Normant, E.; Campo, E.; et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in zebrafish-resistant mantle cell lymphoma. *Leukemia* 2014, 28, 2049–2059. [CrossRef]

134. Siu, K.T.; Ramachandran, J.; Yee, A.J.; Eda, H.; Santo, L.; Panaroni, C.; Mertz, J.A.; Ii, R.J.S.; Cooper, M.R.; Raje, N. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. *Leukemia* 2017, 31, 1760–1769. [CrossRef]
135. Hogg, S.; Vervoort, S.J.; Deswal, S.; Ott, C.J.; Li, J.; Cluse, L.A.; Beavis, P.; Darcy, P.; Martin, B.P.; Spencer, A.; et al. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Rep. 2017, 18, 2162–2174. [CrossRef]

136. Tanaka, M.; Roberts, J.M.; Seo, H.S.; Souza, A.; Paulk, J.; Scott, T.G.; DeAngelo, S.L.; Dhe-Paganon, S.; Bradner, J.E. Design and characterization of bivalent BET inhibitors. Nat. Chem. Biol. 2016, 12, 1089–1096. [CrossRef] [PubMed]

137. Zhao, X.; Lwin, T.; Zhang, X.; Huang, A.; Wang, J.; Marquez, V.E.; Chen-Kiang, S.; Dalton, W.S.; Sotomayor, E.; Tao, J. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013, 27, 2341–2350. [CrossRef]

138. Liu, S.; Li, F.; Pan, L.; Yang, Z.; Shu, Y.; Lv, W.; Dong, P.; Gong, W. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo. Cancer Sci. 2019, 110, 2493–2506. [CrossRef]

139. Hölscher, A.S.; Schulz, W.A.; Pinkerneil, M.; Niegisch, G.; Hoffmann, M.J. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cells. Clin. Epigenetics 2018, 10, 1–14. [CrossRef]

140. Borbely, G.; Haldosen, L.-A.; Dahlman-Wright, K.; Zhao, C. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Cell. Mol. Life Sci. 2019, 76, 3633–3655. [CrossRef]

141. Meng, W.; Wang, B.; Mao, W.; Wang, J.; Zhao, Y.; Li, Q.; Zhang, C.; Tang, Y.; et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer. Cancer Discov. 2017, 7, 852–867. [CrossRef] [PubMed]

142. Bhadury, J.; Nilsson, L.M.; Muradalharan, S.V.; Green, L.C.; Li, Z.; Gesner, E.M.; Hansen, H.C.; Keller, U.B.; McLure, K.G.; Nilsson, J.A. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc. Natl. Acad. Sci. USA 2014, 111, E2721–E2730. [CrossRef] [PubMed]

143. Zhao, L.; Okhovat, J.-P.; Hong, E.K.; Kim, Y.H.; Wood, G.S. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. Neoplasia 2019, 21, 82–92. [CrossRef] [PubMed]

144. Heinemann, A.; Cullinane, C.; De Paoli-Iseppi, R.; Wilmott, J.; Gunatilake, D.; Madore, J.; Strbenac, D.; Yang, J.; Gowrishankar, K.; Shahbazi, J.; Liu, P.Y.; Atmadibrata, B.; Bradner, J.E.; Marshall, G.M.; Lock, R.; Liu, T. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin. Cancer Res. 2016, 22, 2534–2544. [CrossRef] [PubMed]

145. Cortiguera, M.G.; Garcia-Gaipo, L.; Wagner, S.D.; León, J.; Batlle-López, A.; Delgado, M.D. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Sci. Rep. 2019, 9, 16495. [CrossRef]

146. Mazar, P.K.; Herner, A.; Mello, S.S.; With, M.; Hausmann, S.; Sánchez-Rivera, F.J.; Loßgen, S.M.; Kuschma, T.; Hahn, S.; Vangala, D.; et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med. 2015, 21, 1163–1171. [CrossRef] [PubMed]

147. Zhang, X.; Zeger, T.; Weiser, T.; Hamdan, F.; Berger, B.; Lucas, R.; Balourdas, D.; Ladijgan, S.; Cheung, P.F.; Liwers, S.; et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Int. J. Cancer 2020, 147, 2847–2861. [CrossRef]

148. He, S.; Dong, G.; Li, Y.; Wu, S.; Wang, W.; Sheng, C. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer. Angew. Chem. Int. Ed. 2020, 59, 3028–3032. [CrossRef] [PubMed]

149. Enßle, J.C.; Boedicker, C.; Wanior, M.; Vogler, M.; Knapp, S.; Fulda, S. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Cancer Lett. 2018, 428, 160–172. [CrossRef] [PubMed]

150. Alonso, I.; Wilder-Romans, K.; Dommeti, V.L.; Krishnamurthy, P.M.; Apel, I.J.; Escara-Wilke, J.; Plymarte, S.R.; Navone, N.M.; Wang, S.; Feng, F.Y.; et al. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol. Cancer Res. 2016, 14, 324–331. [CrossRef]

151. Alhoud, J.F.; Woolley, J.F.; Al Moustafa, A.-E.; Malki, M.I. DNA Damage/Repair Management in Cancers. Cancers 2020, 12, 1050. [CrossRef]

152. Scully, R.; Chen, J.; Plug, A.; Xiao, Y.; Weaver, D.; Feunteun, J.; Ashley, T.; Livingston, D.M. Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells. Cell 1997, 88, 265–275. [CrossRef]

153. Wright, W.D.; Shah, S.S.; Heyer, W.-D. Homologous recombination and the repair of DNA double-strand breaks. J. Biol. Chem. 2018, 293, 10524–10535. [CrossRef] [PubMed]

154. Zhao, J.; Steinfeld, J.B.; Liang, F.; Chen, X.; Maranon, D.G.; Ma, C.J.; Kwén, Y.; Rao, T.; Wang, W.; Sheng, C.; et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nat. Cell Biol. 2017, 550, 360–365. [CrossRef] [PubMed]

155. Litman, R.; Peng, M.; Jin, Z.; Zhang, F.; Zhang, J.; Powell, S.; Andressen, P.R.; Cantor, S.B. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005, 8, 255–265. [CrossRef]
159. Cantor, S.B.; Bell, D.W.; Ganesan, S.; Kass, E.M.; Drapkin, R.; Grossman, S.; Wahrer, D.C.; Sgroi, D.C.; Lane, W.S.; Haber, D.A.; et al. BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function. Cell 2001, 105, 149–160. [CrossRef]

160. Taniguchi, T.; Garcia-Higuera, I.; Andreassen, P.R.; Gregory, R.C.; Grompe, M.; D’Andrea, A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100, 2414–2420. [CrossRef]

161. Hussain, S.; Wilson, J.B.; Medhurst, A.L.; Hejna, J.; Witt, E.; Ananth, S.; Davies, A.; Mason, J.-Y.; Moses, R.; West, S.C.; et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Nat. Struct. Mol. Biol. 2020, 27, 240–248. [CrossRef]

162. Alcón, P.; Shakeel, S.; Chen, Z.A.; Rappsilber, J.; Patel, K.J.; Passmore, L.A. FANCD2–FANCI is a clamp stabilized on DNA by monoubiquitination of FANCD2 during DNA repair. Nat. Struct. Mol. Biol. 2020, 27, 240–248. [CrossRef]

163. Neizer-Ashun, F.; Bhattacharya, R. Reality CHEK: Understanding the biology and clinical potential of CHK1. Cancer Lett. 2021, 497, 202–211. [CrossRef]

164. Stracker, T.H.; Petrini, J.H. The MRE11 complex: Starting from the ends. Nat. Rev. Mol. Cell Biol. 2011, 12, 90–103. [CrossRef]

165. Bassi, C.; Li, Y.-T.; Khu, K.; Mateo, F.; Baniasadi, P.S.; Elia, A.; Mason, J.; Stambolic, V.; Pujana, M.A.; Mak, T.W.; et al. The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair. Cell Death Differ. 2016, 23, 1198–1208. [CrossRef]

166. Russell, P.; Nurse, P. Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 1987, 49, 559–567. [CrossRef]

167. Zeidler, M.; Varambally, S.; Cao, Q.; Chinnaiyan, A.M.; Ferguson, D.O.; Merajver, S.D.; Kleer, C.G. The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. Neoplasia 2005, 7, 1011–1019. [CrossRef]

168. Stanlie, A.; Yousif, A.; Akiyama, H.; Honjo, T.; Begum, N.A. Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining. Mol. Cell 2014, 55, 97–110. [CrossRef] [PubMed]

169. Gainor, J.F.; Longo, D.L.; Chabner, B.A. Pharmacodynamic Biomarkers: Falling Short of the Mark? Clin. Cancer Res. 2014, 20, 2587–2594. [CrossRef]

170. Mita, M.M.; Mita, A.C. Bromodomain inhibitors a decade later: A promise unfulfilled? Br. J. Cancer 2020, 123, 1713–1714. [CrossRef]

171. Yi, J.; Liu, C.; Tao, Z.; Wang, M.; Jia, Y.; Sang, X.; Shen, L.; Xue, Y.; Jiang, K.; Luo, F.; et al. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine 2019, 43, 225–237. [CrossRef] [PubMed]

172. Carey, J.P.; Karakas, C.; Bui, T.; Chen, X.; Vijayaraghavan, S.; Zhao, Y.; Wang, J.; Mikule, K.; Litton, J.K.; Hunt, K.K.; et al. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2017, 78, 742–757. [CrossRef]